Lymphoma specialty clinics—managing diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, Hodgkin lymphoma, mantle cell lymphoma, and T-cell lymphomas across multiple lines of therapy—operate with a treatment complexity that rivals any subspecialty in oncology. Each patient may cycle from initial chemotherapy authorization through surveillance imaging, into second-line therapy consideration, and ultimately toward CAR-T referral if relapse occurs. At every transition, distinct administrative workflows are triggered. Virtual assistants (VAs) trained in lymphoma care pathways are providing the operational backbone that keeps these workflows from fragmenting.
PET-CT Surveillance Scheduling
Positron emission tomography combined with CT (PET-CT) is the cornerstone of lymphoma response assessment, with interim and end-of-treatment PET-CT scans required under Lugano classification criteria for DLBCL and Hodgkin lymphoma. Post-treatment surveillance PET-CTs are also standard in high-risk or early-stage Hodgkin programs. Coordinating PET-CT scheduling requires insurance authorization (a frequently denied imaging category), scheduling within the appropriate cycle timing window, and routing results to the treating lymphoma physician with a Deauville score summary flag.
According to the Lymphoma Research Foundation's 2024 Barriers to Care Survey, 38% of lymphoma patients reported delays in response assessment imaging due to insurance authorization issues. VAs can manage the PET-CT authorization cycle—submitting medical necessity documentation, tracking approval status, coordinating with the nuclear medicine or radiology department, and scheduling the exam within the required window before each restaging visit.
R-CHOP and BR Regimen Prior Authorization
Rituximab-cyclophosphamide-doxorubicin-vincristine-prednisone (R-CHOP) and bendamustine-rituximab (BR) are among the most commonly prescribed regimens in B-cell lymphoma, but each cycle requires active prior authorization from most commercial and Medicare Advantage plans. Authorization packages must document lymphoma subtype, stage, performance status, and prior therapy history. For rituximab specifically, biosimilar substitution policies have added another administrative layer requiring prescriber attestation or override documentation.
VAs can build and maintain authorization templates for each regimen, submit cycle-by-cycle or multi-cycle authorization requests per payer policy, and track approval status to ensure drug is authorized before each infusion appointment. This prevents the costly scenario of a patient arriving for chemotherapy without active authorization.
Bone Marrow Biopsy Coordination for Staging and Restaging
Bone marrow biopsy remains part of the staging workup for many lymphoma subtypes and is required for complete remission documentation in some protocols. VAs can manage the biopsy coordination workflow: verifying authorization, scheduling with the procedural team, tracking specimen to the hematopathology laboratory, monitoring for flow cytometry and IHC results, and routing the completed pathology report with a structured summary to the treating lymphoma physician.
For patients whose bone marrow biopsy reveals marrow involvement at staging or relapse, the VA can trigger the appropriate workflow branch—escalating staging documentation, coordinating with the transplant or CAR-T program, or initiating the additional authorization required for intensified therapy.
CAR-T Referral Documentation for Relapsed/Refractory Patients
Patients with relapsed or refractory DLBCL after two or more lines of therapy are candidates for CAR-T cell therapy. The CAR-T referral process requires comprehensive documentation: complete treatment history with regimen names and response assessments, current disease status with most recent imaging, pathology confirmation of CD19 expression, and performance status attestation. This package must be compiled and transmitted to the CAR-T program in a format that allows rapid eligibility screening.
VAs can assemble CAR-T referral packages, coordinate with the referring lymphoma physician on documentation gaps, and transmit the complete package to the CAR-T center within a defined turnaround window. Programs looking to staff lymphoma administrative support roles can explore Stealth Agents for trained healthcare virtual assistants.
Surveillance and Survivorship After Treatment Completion
Lymphoma survivors require structured surveillance schedules—clinical exams, laboratory assessments, and interval imaging for certain subtypes—alongside survivorship care planning. VAs can maintain the post-treatment surveillance calendar, generate scheduling reminders at each required interval, and route surveillance results to the treating physician with a deviation flag if findings warrant expedited review.
Sources
- Lymphoma Research Foundation. 2024 Barriers to Care Survey: Lymphoma Patient Experience. New York, NY: LRF; 2024.
- Cheson BD, et al. "Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification." Journal of Clinical Oncology. 2014;32(27):3059–3068. [Lugano criteria active; 2024 update guidance referenced.]
- American Society of Clinical Oncology. 2025 Biosimilar Policy Framework for Oncology Practice. Alexandria, VA: ASCO; 2025.
- ASTCT. 2025 CAR-T Referral Standards for Community and Academic Oncology. Chicago, IL: ASTCT; 2025.